Cargando…

Impact of Comorbidities on Survival Among Patients with Chronic Myeloid Leukaemia Using the Charlson Comorbidity Index: Retrospective study from Basra, Iraq

OBJECTIVES: In chronic diseases, comorbidities are known to have a strong negative association with overall survival (OS). This study aimed to use the Charlson Comorbidity Index (CCI) to examine the effect of comorbidities on OS among patients with chronic myeloid leukaemia (CML) treated with tyrosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Abood, Rafid A., Hasson, Hasson M., Khalaf, Asaad A., Saleh, Elaf M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sultan Qaboos University Medical Journal, College of Medicine & Health Sciences 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839677/
https://www.ncbi.nlm.nih.gov/pubmed/31728222
http://dx.doi.org/10.18295/squmj.2019.19.03.010
_version_ 1783467478318317568
author Abood, Rafid A.
Hasson, Hasson M.
Khalaf, Asaad A.
Saleh, Elaf M.
author_facet Abood, Rafid A.
Hasson, Hasson M.
Khalaf, Asaad A.
Saleh, Elaf M.
author_sort Abood, Rafid A.
collection PubMed
description OBJECTIVES: In chronic diseases, comorbidities are known to have a strong negative association with overall survival (OS). This study aimed to use the Charlson Comorbidity Index (CCI) to examine the effect of comorbidities on OS among patients with chronic myeloid leukaemia (CML) treated with tyrosine kinase inhibitors. METHODS: This retrospective study was conducted between January 2006 and October 2016 and included 247 CML patients treated at the Basra Oncology & Haematology Centre, Basra, Iraq. Information from hospital records was used to calculate CCI scores and patients were divided into groups based on scores of 2–3 (CCI1 group) or ≥4 (CCI2 group). The OS was calculated using Kaplan-Meier curves. RESULTS: There were 177 (71.7%) patients in the CCI1 group and 70 (28.3%) in the CCI2 group. Overall, patients in the CCI1 group were significantly younger compared to those in the CCI2 group (median age: 35 versus 60 years; P <0.001); however, the gender distribution was similar in both groups (male-to-female ratio of 1:1.06 versus 1:1.18, respectively; P = 0.683). Diabetes mellitus was the most common comorbidity (17%), followed by hypertension (12%) and gastrointestinal diseases (6%). There were no significant differences in mortality between the groups (9.6% versus 8.6%; P = 0.801). In total, 69.6% of all deaths were related to CML progression rather than to the presence of comorbidities. CONCLUSION: No significant correlation was found between CCI score and OS among CML patients in Basra. However, larger long-term prospective studies are needed to evaluate associations with median age at diagnosis and disease severity and to develop region-specific prognostic scales.
format Online
Article
Text
id pubmed-6839677
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Sultan Qaboos University Medical Journal, College of Medicine & Health Sciences
record_format MEDLINE/PubMed
spelling pubmed-68396772019-11-14 Impact of Comorbidities on Survival Among Patients with Chronic Myeloid Leukaemia Using the Charlson Comorbidity Index: Retrospective study from Basra, Iraq Abood, Rafid A. Hasson, Hasson M. Khalaf, Asaad A. Saleh, Elaf M. Sultan Qaboos Univ Med J Clinical & Basic Research OBJECTIVES: In chronic diseases, comorbidities are known to have a strong negative association with overall survival (OS). This study aimed to use the Charlson Comorbidity Index (CCI) to examine the effect of comorbidities on OS among patients with chronic myeloid leukaemia (CML) treated with tyrosine kinase inhibitors. METHODS: This retrospective study was conducted between January 2006 and October 2016 and included 247 CML patients treated at the Basra Oncology & Haematology Centre, Basra, Iraq. Information from hospital records was used to calculate CCI scores and patients were divided into groups based on scores of 2–3 (CCI1 group) or ≥4 (CCI2 group). The OS was calculated using Kaplan-Meier curves. RESULTS: There were 177 (71.7%) patients in the CCI1 group and 70 (28.3%) in the CCI2 group. Overall, patients in the CCI1 group were significantly younger compared to those in the CCI2 group (median age: 35 versus 60 years; P <0.001); however, the gender distribution was similar in both groups (male-to-female ratio of 1:1.06 versus 1:1.18, respectively; P = 0.683). Diabetes mellitus was the most common comorbidity (17%), followed by hypertension (12%) and gastrointestinal diseases (6%). There were no significant differences in mortality between the groups (9.6% versus 8.6%; P = 0.801). In total, 69.6% of all deaths were related to CML progression rather than to the presence of comorbidities. CONCLUSION: No significant correlation was found between CCI score and OS among CML patients in Basra. However, larger long-term prospective studies are needed to evaluate associations with median age at diagnosis and disease severity and to develop region-specific prognostic scales. Sultan Qaboos University Medical Journal, College of Medicine & Health Sciences 2019-08 2019-11-05 /pmc/articles/PMC6839677/ /pubmed/31728222 http://dx.doi.org/10.18295/squmj.2019.19.03.010 Text en © Copyright 2019, Sultan Qaboos University Medical Journal, All Rights Reserved This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nd/4.0/) .
spellingShingle Clinical & Basic Research
Abood, Rafid A.
Hasson, Hasson M.
Khalaf, Asaad A.
Saleh, Elaf M.
Impact of Comorbidities on Survival Among Patients with Chronic Myeloid Leukaemia Using the Charlson Comorbidity Index: Retrospective study from Basra, Iraq
title Impact of Comorbidities on Survival Among Patients with Chronic Myeloid Leukaemia Using the Charlson Comorbidity Index: Retrospective study from Basra, Iraq
title_full Impact of Comorbidities on Survival Among Patients with Chronic Myeloid Leukaemia Using the Charlson Comorbidity Index: Retrospective study from Basra, Iraq
title_fullStr Impact of Comorbidities on Survival Among Patients with Chronic Myeloid Leukaemia Using the Charlson Comorbidity Index: Retrospective study from Basra, Iraq
title_full_unstemmed Impact of Comorbidities on Survival Among Patients with Chronic Myeloid Leukaemia Using the Charlson Comorbidity Index: Retrospective study from Basra, Iraq
title_short Impact of Comorbidities on Survival Among Patients with Chronic Myeloid Leukaemia Using the Charlson Comorbidity Index: Retrospective study from Basra, Iraq
title_sort impact of comorbidities on survival among patients with chronic myeloid leukaemia using the charlson comorbidity index: retrospective study from basra, iraq
topic Clinical & Basic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839677/
https://www.ncbi.nlm.nih.gov/pubmed/31728222
http://dx.doi.org/10.18295/squmj.2019.19.03.010
work_keys_str_mv AT aboodrafida impactofcomorbiditiesonsurvivalamongpatientswithchronicmyeloidleukaemiausingthecharlsoncomorbidityindexretrospectivestudyfrombasrairaq
AT hassonhassonm impactofcomorbiditiesonsurvivalamongpatientswithchronicmyeloidleukaemiausingthecharlsoncomorbidityindexretrospectivestudyfrombasrairaq
AT khalafasaada impactofcomorbiditiesonsurvivalamongpatientswithchronicmyeloidleukaemiausingthecharlsoncomorbidityindexretrospectivestudyfrombasrairaq
AT salehelafm impactofcomorbiditiesonsurvivalamongpatientswithchronicmyeloidleukaemiausingthecharlsoncomorbidityindexretrospectivestudyfrombasrairaq